IDH2 and acute myeloid leukemia: Thus, presence of non-mutation IDH alongside Suppressyn could be a potentially underlying biological factor that affects patients, particularly individuals with IDH-mutated AML after hematopoietic stem cell transplantation (HSCT)(Bill et al., 2023).